Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.

Bibliographic Details
Main Authors:	De Leenheer, E, Vanderkerken, K, Bakkus, M, Van Camp, B, Shipman, C, Croucher, P
Format:	Conference item
Published:	2002

Similar Items

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
by: De Leenheer, E, et al.
Published: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
by: Shipman, C, et al.
Published: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
by: Shipman, C, et al.
Published: (2002)

Bone metabolism and RANKL/RANK/OPG trail in periodontal disease
by: Czupkallo Lukasz, et al.
Published: (2016-12-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
by: Locklin, R, et al.
Published: (2005)

Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT
by: Hemingway, F, et al.
Published: (2013)

Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT.
by: Hemingway, F, et al.
Published: (2013)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
by: Lili Zhang, et al.
Published: (2016-11-01)

Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis
by: Asieh Mansour, et al.
Published: (2018-07-01)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
by: Croucher, P, et al.
Published: (2001)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
by: Vanderkerken, K, et al.
Published: (2003)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
by: Clive Henry Buckle, et al.
Published: (2012-01-01)

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
by: Margarita Ivanova, et al.
Published: (2021-05-01)

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies
by: Yan Zhang, et al.
Published: (2022-12-01)

Effect of enhanced masticatory force on OPG, RANKL and MGF in alveolar bone of ovariectomized rats
by: Zongmin Ma, et al.
Published: (2020-04-01)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
by: Shipman, C, et al.
Published: (2002)

Salidroside Improves Bone Histomorphology and Prevents Bone Loss in Ovariectomized Diabetic Rats by Upregulating the OPG/RANKL Ratio
by: Hongxing Zheng, et al.
Published: (2018-09-01)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Bisphosphonates and in vivo models of multiple myeloma - Reply
by: Shipman, C, et al.
Published: (2001)

RANK/RANKL/OPG LIGAND-RECEPTOR SYSTEM AND ITS ROLE IN PRIMARY BONE NEOPLASMS (LITERATURE ANALYSIS AND OWN DATA)
by: E. S. Gershtein, et al.
Published: (2015-12-01)

Biology of the RANKL-RANK-OPG System
by: Yongwon eChoi, et al.
Published: (2014-10-01)

Bone Metabolism and RANKL/OPG Ratio in Rheumatoid Arthritis Women Treated with TNF-α Inhibitors
by: Agnieszka Jura-Półtorak, et al.
Published: (2021-06-01)

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
by: Marco Infante, et al.
Published: (2019-01-01)

The RANK/ RANKL/ OPG interaction in the repair of autogenous bone grafts in female rats with estrogen deficiency
by: Tábata de Mello TERA, et al.
Published: (2014-01-01)

RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects
by: C. Di Nisio, et al.
Published: (2015-02-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
by: Shipman, C, et al.
Published: (2003)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
by: Riham Eid, et al.
Published: (2023-06-01)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

The inhibition of Wnt signaling attenuates RANKL-induced osteoclastogenic macrophage activation
by: Dai Yamanouchi, et al.
Published: (2023-07-01)

The Effects of Acute Exercise on RANKL/RANK/OPG Pathway and Bone Metabolic Markers in Healthy College Female
by: Ji-Yeon Kim, et al.
Published: (2018-08-01)

"Single nucleotide polymorphisms of the <it>OPG/RANKL </it>system genes in primary hyperparathyroidism and their relationship with bone mineral density"
by: Piedra María, et al.
Published: (2011-12-01)

Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection.
by: Kehmia Titanji, et al.
Published: (2014-10-01)

RANK/RANKL/OPG system in the intervertebral disc
by: Norihiko Takegami, et al.
Published: (2017-06-01)

Salivary level of RANKL and OPG in chronic periodontitis
by: Batool H Al-Ghurabi, et al.
Published: (2015-03-01)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
by: Locklin, R, et al.
Published: (2007)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
by: Croucher, P, et al.
Published: (2002)